A pending U.S. regulatory action under White House review could expand access to certain peptides via pharmacy compounding. The American Academy of Peptide Medicine is scheduled to meet with the Office of Management and Budget to discuss the proposal after a July advisory panel to the FDA narrowly recommended adding several peptides to the list of products eligible for compounding. The article notes concerns from FDA scientists and highlights how “compounded” products can become a pathway for substances used by wellness-focused communities. Alliance for Pharmacy Compounding CEO Scott Brunner said the notice could be significant but that details on which peptides and conditions would be covered are not yet clear. For biotech and health-system stakeholders, the key issue is that regulatory scope—particularly definitions and eligibility—can quickly alter market demand for peptide ingredients, supply chains, and clinical oversight practices.